IP Library › Patent Application 19278990
Patent Application
App. No. 19/278,990

METHODS OF TUMOR VACCINATION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/278,990
Abstract

Provided herein are methods for treating a tumor or generating an immune response against a tumor in a subject in need, including one or more intratumoral administration steps each comprising administering to the subject at a tumor site, an effective amount of a first composition, and one or more vaccination steps each comprising administering to the subject at a site distal to the tumor site, an effective amount of a second composition. The first and second composition may each comprise an allogeneic leukemia-derived cell that is useful in eliciting an immune response against the tumor.

Claims (33)

1 . A method for treating a tumor in a subject in need thereof, comprising:

one or more intratumoral administration steps each comprising administering to the subject at a tumor site, an effective amount of a first composition comprising an allogeneic leukemia-derived cell; and

one or more vaccination steps each comprising administering to the subject at a site distal to the tumor site, an effective amount of a second composition comprising an allogeneic leukemia-derived cell.

2 . The method of claim 1 , wherein the one or more intratumoral administration steps each comprises administering the first composition into the tumor or at a site proximal to the tumor.

3 . The method of claim 2 , wherein the site proximal to the tumor is peritumoral.

4 . The method of claim 1 , wherein the first composition is prepared for intratumoral administration.

5 - 6 . (canceled)

7 . The method of claim 1 , wherein the one or more vaccination steps each comprise intravenously administering the second composition.

8 - 9 . (canceled)

10 . The method of claim 1 , wherein the one or more vaccination steps each comprise intradermally administering the second composition.

11 - 12 . (canceled)

13 . The method of claim 1 , wherein the one or more vaccination steps each comprise intramuscularly administering the second composition.

14 - 17 . (canceled)

18 . The method of claim 1 , wherein the one or more intratumoral administration steps are performed before the one or more vaccination steps.

19 . The method of claim 1 , wherein the one or more intratumoral administration steps are performed after the one or more vaccination steps.

20 . The method of claim 1 , further comprising one or more vaccination steps following the one or more intratumoral administration steps.

21 - 24 . (canceled)

25 . The method of claim 1 , wherein the time between the one or more intratumoral administration steps and the one or more vaccination steps is sufficient for an immune response to be mounted as a result of the first vaccination step of the one or more vaccination steps.

26 . The method of claim 25 , wherein the time between the one or more intratumoral administration steps and the one or more vaccination steps is about 2 days to about 21 days.

27 - 30 . (canceled)

31 . The method of claim 20 , wherein the time between the one or more vaccination steps following the one or more intratumoral administration steps, and the one or more intratumoral administration steps is sufficient for an immune response to be mounted as a result of the first vaccination step of the one or more vaccination steps.

32 - 36 . (canceled)

37 . The method of claim 1 , wherein the allogeneic leukemia-derived cell comprises at least one tumor associated antigen or a nucleic acid encoding at least one tumor associated antigen that is associated with the tumor in the subject.

38 - 40 . (canceled)

41 . The method of claim 1 , wherein the allogeneic leukemia-derived cell comprises a dendritic cell phenotype.

42 . The method of claim 1 , wherein the allogeneic leukemia-derived cell comprises a mature dendritic cell phenotype.

43 - 44 . (canceled)

45 . The method of claim 1 , wherein the allogeneic leukemia-derived cell is CD34-positive, CD1a-positive, and CD83-positive.

46 . The method of claim 1 , wherein the allogeneic leukemia-derived cell expresses a cell surface marker selected from the group consisting of DC-SIGN, Langerin, CD80, CD86, CD70, CD40, and any combination thereof.

47 - 48 . (canceled)

49 . The method of claim 1 , wherein the allogeneic leukemia-derived cell is derived from the DCOne cell line.

50 . The method of claim 1 , wherein the allogeneic leukemia-derived cell has been inactivated.

51 - 63 . (canceled)